01:34 PM EDT, 07/30/2024 (MT Newswires) -- Imunon ( IMNN ) said Tuesday that topline data from a phase 2 trial of IMNN-001 in patients with advanced ovarian cancer showed an 11.1-month increase in median overall survival compared with treatment with standard-of-care alone.

Shares surged 154% as intraday trading volume catapulted to more than 119.1 million from a daily average of about 103,000.

AGAPE ATP Corp. ( ATPC ) disclosed on Tuesday separate collaboration agreements to venture into projects in the pain management and elderly care solutions market.

Shares soared 80% as intraday trading volume advanced to more than 185.5 million versus the stock's daily average of about 2.5 million.

Processa Pharmaceuticals ( PCSA ) said Tuesday the US Food and Drug Administration cleared its investigational new drug application for the next-generation capecitabine, its lead product candidate.

The IND supports the initiation of a phase 2 clinical trial in patients with advanced or metastatic breast cancer. The study will likely begin enrollment in Q3.

Shares jumped 25% as intraday trading volume climbed to over 55.2 million from a daily average of about 91,000.

Price: 2.99, Change: +1.81, Percent Change: +153.39